Vestal Point Capital LP Buys Shares of 2,924,216 Nyxoah S.A. (NASDAQ:NYXH)

Vestal Point Capital LP purchased a new position in Nyxoah S.A. (NASDAQ:NYXH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,924,216 shares of the company's stock, valued at approximately $23,394,000. Nyxoah makes up about 1.4% of Vestal Point Capital LP's holdings, making the stock its 28th largest position. Vestal Point Capital LP owned approximately 8.59% of Nyxoah as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. LPL Financial LLC purchased a new position in Nyxoah in the 4th quarter worth approximately $102,000. Walleye Capital LLC increased its holdings in shares of Nyxoah by 23.9% in the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock valued at $119,000 after purchasing an additional 2,862 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Nyxoah in the fourth quarter valued at approximately $135,000. Geode Capital Management LLC lifted its position in Nyxoah by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after buying an additional 2,774 shares in the last quarter. Finally, Kovack Advisors Inc. lifted its position in Nyxoah by 100.0% during the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company's stock worth $160,000 after buying an additional 10,000 shares in the last quarter.

Nyxoah Trading Up 3.4%

Shares of Nyxoah stock traded up $0.27 during trading hours on Thursday, hitting $8.32. The company's stock had a trading volume of 192,413 shares, compared to its average volume of 74,751. The stock has a market cap of $283.38 million, a price-to-earnings ratio of -4.45 and a beta of 1.56. Nyxoah S.A. has a twelve month low of $5.55 and a twelve month high of $11.87. The firm has a fifty day moving average of $7.05 and a 200-day moving average of $8.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28.

Nyxoah (NASDAQ:NYXH - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. The company had revenue of $1.12 million during the quarter, compared to analyst estimates of $1.64 million. Research analysts forecast that Nyxoah S.A. will post -1.91 EPS for the current year.

Wall Street Analyst Weigh In

NYXH has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Nyxoah in a report on Tuesday, April 8th. Stifel Nicolaus lowered their price target on shares of Nyxoah from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Monday, April 21st.

Nyxoah Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.